Study on the effect of Jianpi Yiqi decoction on clinical symptoms, inflammation, oxidative stress, efficacy and adverse reactions in sufferers with colorectal cancer.

Colorectal cancer is a type of cancer that affects the colon or rectum, which are part of the digestive system. It usually develops from small growths called polyps that can turn cancerous over time. This study aimed to investigate the effects of Jianpi Yiqi prescription on clinical symptoms, inflammation, oxidative stress, efficacy, and adverse reactions in colorectal cancer (CRC) patients. A total of 84 CRC patients treated at a hospital from January 2020 to December 2021 were randomly divided into two groups: the conventional chemotherapy group and the Jianpi Yiqi prescription group. Patients in the Jianpi Yiqi group received traditional Chinese medicine on top of conventional chemotherapy. Clinical symptoms and plasma biomarkers were analyzed and compared between the two groups. Results showed that there were significant differences between the two groups before therapy. After therapy, the Jianpi Yiqi group had lower TCM symptom scores, inflammatory factor indices, MDA and SOD levels, and incidence of adverse reactions than the conventional group. Moreover, the total effective rate and tumor stability rate of the Jianpi Yiqi group were higher than those of the conventional group. The study concluded that Jianpi Yiqi prescription had better clinical efficacy in treating CRC patients compared to conventional chemotherapy, with fewer adverse reactions and better inhibition of inflammatory factors and oxidative stress. Overall, this study suggests that Jianpi Yiqi prescription could be a promising complementary therapy for CRC patients, but more research is needed to confirm these findings.